<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Chemotherapy regimens for metastatic colorectal cancer: Modified FOLFOXIRI plus &lt;span style="white-space: nowrap;"&gt;panitumumab&lt;sup&gt;[1]&lt;/sup&gt;&lt;/span&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Chemotherapy regimens for metastatic colorectal cancer: Modified FOLFOXIRI plus <span style="white-space: nowrap;">panitumumab<sup>[1]</sup></span></h1>
<div class="graphic"><div class="figure"><div class="ttl">Chemotherapy regimens for metastatic colorectal cancer: Modified FOLFOXIRI plus <span style="white-space: nowrap;">panitumumab<sup>[1]</sup></span></div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="20%"></colgroup><colgroup width="40%"></colgroup><colgroup width="20%"></colgroup> <tbody> <tr class="divider_bottom"> <td colspan="4"><strong>Cycle length:</strong> 14 days.<br/> <strong>Duration of therapy:</strong> Until disease progression, intolerance, resectability of liver <span style="white-space: nowrap;">metastases.<sup>¶</sup></span></td> </tr> <tr class="divider_top"> <td class="subtitle1 divider_bottom">Drug</td> <td class="subtitle1 divider_bottom">Dose and route</td> <td class="subtitle1 divider_bottom">Administration</td> <td class="subtitle1 divider_bottom">Given on days</td> </tr> <tr> <td>Panitumumab</td> <td>6 mg/kg IV</td> <td>Dilute to a total volume of <span style="white-space: nowrap;">100 mL<sup>Δ</sup></span> with <span style="white-space: nowrap;">NS<sup>◊</sup></span> and administer over <span style="white-space: nowrap;">60 minutes<sup>§</sup></span> using a low-protein-binding 0.2-micron or 0.22-micron in-line filter.</td> <td>Day 1</td> </tr> <tr> <td><span style="white-space: nowrap;">Irinotecan<sup>¥</sup></span></td> <td>150 mg/m<sup>2</sup> IV</td> <td>Dilute with 500 mL <span style="white-space: nowrap;">D5W<sup>◊</sup></span> to a final concentration of 0.12 to 2.8 mg/mL and administer over 60 minutes.</td> <td>Day 1</td> </tr> <tr> <td><span style="white-space: nowrap;">Oxaliplatin<sup>‡</sup></span></td> <td>85 mg/m<sup>2</sup> IV</td> <td>Dilute with 500 mL <span style="white-space: nowrap;">D5W<sup>◊</sup></span> and administer over two hours after irinotecan. Administer concurrently with leucovorin in separate bags via y-line <span style="white-space: nowrap;">connection.<sup>[2]</sup></span></td> <td>Day 1</td> </tr> <tr> <td><span style="white-space: nowrap;">Leucovorin<sup>†</sup></span></td> <td>400 mg/m<sup>2</sup> IV</td> <td>Dilute with 250 mL <span style="white-space: nowrap;">D5W<sup>◊</sup></span> and administer over two hours, concurrent with oxaliplatin.</td> <td>Day 1</td> </tr> <tr class="divider_bottom"> <td>Fluorouracil (FU)</td> <td>2400 to 3000 mg/m<sup>2</sup> IV</td> <td>Dilute in 500 to 1000 mL <span style="white-space: nowrap;">D5W<sup>◊</sup></span> and administer over 48 hours, after leucovorin. To accommodate an ambulatory pump for outpatient treatment, can be administered undiluted (50 mg/mL). The original protocol used 3000 mg/m<sup>2</sup>, but many United States oncologists use a lower starting dose (2400 mg/m<sup>2</sup>) and escalate as tolerated to reach a final dose of 3000 mg/m<sup>2</sup>.</td> <td>Day 1</td> </tr> <tr class="divider_top"> <td class="subtitle1_left" colspan="4">Pretreatment considerations:</td> </tr> <tr> <td class="indent1"><strong>Emesis risk</strong></td> <td colspan="3"> <ul> <li>HIGH (&gt;90% frequency of emesis).**</li> <li>Refer to UpToDate topics on prevention of chemotherapy-induced nausea and vomiting in adults.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan="3"> <ul> <li>Routine premedication not indicated.</li> <li>Refer to UpToDate topics on infusion reactions to systemic chemotherapy.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Vesicant/irritant properties</strong></td> <td colspan="3"> <ul> <li>Oxaliplatin and fluorouracil are irritants, but oxaliplatin can cause significant tissue damage; avoid extravasation.</li> <li>Refer to UpToDate topics on extravasation injury from chemotherapy and other non-antineoplastic vesicants.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Infection prophylaxis</strong></td> <td colspan="3"> <ul> <li>Routine primary prophylaxis with G-CSF is not warranted (estimated risk of febrile neutropenia <span style="white-space: nowrap;">2%<sup>[1]</sup>).</span> However, given the high rate of grade 3 or 4 neutropenia with this regimen (approximately 16%), primary prophylaxis may be considered for high-risk patients.</li> <li>Refer to UpToDate topics on use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan="3"> <ul> <li>A lower starting dose of oxaliplatin and irinotecan may be needed for patients with renal <span style="white-space: nowrap;">insufficiency.<sup>[3,4]</sup></span> A lower starting dose of irinotecan and FU may be needed for patients with hepatic <span style="white-space: nowrap;">impairment.<sup>[4,5]</sup></span> Dose adjustments for irinotecan may be needed for patients with increased serum <span style="white-space: nowrap;">bilirubin.<sup>[4]</sup></span></li> <li>Refer to UpToDate topics on chemotherapy hepatotoxicity and dose modification in patients with liver disease, conventional cytotoxic agents; chemotherapy hepatotoxicity and dose modification in patients with liver disease, molecularly targeted agents; and chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency, conventional cytotoxic agents.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Maneuvers to prevent neurotoxicity</strong></td> <td colspan="3"> <ul> <li>Pharmacologic methods to prevent/delay the onset of oxaliplatin-related neuropathy are controversial due to the absence of large clinical trials proving benefit. Counsel patients to avoid exposure to cold during and for approximately 48 hours after each <span style="white-space: nowrap;">infusion.<sup>[3]</sup></span> Prolongation of the oxaliplatin infusion time from two to six hours may mitigate acute neurotoxicity.</li> <li>Refer to UpToDate topics on overview of neurologic complications of platinum-based chemotherapy.</li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1"><strong>Cardiac issues</strong></td> <td colspan="3"> <ul> <li>QT prolongation and ventricular arrhythmias have been reported after oxaliplatin. ECG monitoring is recommended in certain settings (patients with heart failure, bradyarrhythmias, coadministration of drugs known to prolong the QT interval, or electrolyte abnormalities). Avoid oxaliplatin in patients with congenital long QT syndrome. Correct hypokalemia and hypomagnesemia prior to initiating oxaliplatin.</li> </ul> </td> </tr> <tr class="divider_top"> <td class="subtitle1_left" colspan="4">Monitoring parameters:</td> </tr> <tr> <td colspan="4"> <ul class="decimal_heading"> <li>CBC with differential and platelet count prior to each treatment.</li> </ul> </td> </tr> <tr> <td colspan="4"> <ul class="decimal_heading"> <li>Assess electrolytes (including magnesium, calcium, and potassium) and liver and renal function prior to each dose. Monitor serum calcium, magnesium, and potassium levels weekly for eight weeks after completion of <span style="white-space: nowrap;">therapy.<sup>[6]</sup></span></li> </ul> </td> </tr> <tr> <td colspan="4"> <ul class="decimal_heading"> <li>Irinotecan is associated with early and late diarrhea, both of which may be <span style="white-space: nowrap;">severe.<sup>[4]</sup></span> Patients must be instructed in the early use of loperamide for late diarrhea. Patients who develop diarrhea should be closely monitored, and supportive care measures (eg, fluid and electrolyte replacement, loperamide, antibiotics, etc) should be provided as needed. For patients who develop abdominal cramping and/or diarrhea within 24 hours of receiving irinotecan, administer atropine (0.3 to 0.6 mg IV) and premedicate with atropine for later cycles.</li> <li>Refer to UpToDate topics on enterotoxicity of chemotherapeutic agents.</li> </ul> </td> </tr> <tr> <td colspan="4"> <ul class="decimal_heading"> <li>Monitor for skin rash and for evidence of keratitis or ulcerative keratitis.</li> </ul> </td> </tr> <tr> <td colspan="4"> <ul class="decimal_heading"> <li>Monitor for signs or symptoms of pulmonary toxicity.</li> </ul> </td> </tr> <tr class="divider_bottom"> <td colspan="4"> <ul class="decimal_heading"> <li>Assess changes in neurologic function prior to each treatment.</li> </ul> </td> </tr> <tr class="divider_top"> <td class="subtitle1_left" colspan="4">Suggested dose modifications for toxicity:</td> </tr> <tr class="divider_bottom"> <td class="indent1" colspan="4"><strong>The specific dose alteration parameters for the modified FOLFOXIRI plus panitumumab regimen in colorectal cancer patients were published as a supplement to the original phase II <span style="white-space: nowrap;">trial.<sup>[1]</sup></span></strong></td> </tr> <tr> <td class="indent1"><strong>Myelotoxicity</strong></td> <td colspan="3"> <ul> <li>Do not start a new cycle of therapy unless granulocyte count is ≥1500/microL and platelet count is <span style="white-space: nowrap;">&gt;75,000/microL.<sup>[1]</sup></span></li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Neutropenia</strong></td> <td colspan="3"> <ul> <li>For grade 3 or 4 neutropenia without fever during prior cycle, or febrile neutropenia with neutrophil count ≥0.5 to &lt;1.0 × <span style="white-space: nowrap;">10<sup>9</sup>/L</span> and no life-threatening sepsis, reduce doses of all cytotoxic agents by 25% once recovered, and initiate prophylactic G-CSF, if not given <span style="white-space: nowrap;">previously.<sup>[1]</sup></span> For febrile neutropenia with neutrophil count &lt;0.5 × <span style="white-space: nowrap;">10<sup>9</sup>/L</span> or life-threatening sepsis, reduce doses of all cytotoxic agents by 50% for the next cycle, once recovered, and initiate prophylactic G-CSF, if not given previously. For patients with febrile septic neutropenia with diarrhea, initiate secondary prophylaxis with G-CSF, and antibiotic prophylaxis with levofloxacin 500 mg once daily. For second occurrence of grade 3 or 4 neutropenia without fever, reduce doses of all cytotoxic agents to 50% of original. If nonrecovery after three weeks, or third occurrence of grade 3 or 4 neutropenia without fever, or second recurrence of febrile neutropenia, discontinue treatment unless it is in the patient's best interest to continue on FU plus leucovorin with or without panitumumab.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Thrombocytopenia</strong></td> <td colspan="3"> <ul> <li>For nadir platelet count &lt;50,000/microL, reduce doses of all cytotoxic agents by 25%, once <span style="white-space: nowrap;">recovered.<sup>[1]</sup></span> For second occurrence, reduce doses of all cytotoxic agents to 50% of original dose, once recovered. If nonrecovery after three weeks' delay or third occurrence of platelets &lt;50,000/microL, discontinue treatment unless it is in the patient's best interest to continue on FU plus leucovorin with or without panitumumab.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Diarrhea</strong></td> <td colspan="3"> <ul> <li>Do not start a new cycle of therapy until resolution of diarrhea to grade 1 or less without antidiarrheal <span style="white-space: nowrap;">medication.<sup>[1]</sup></span></li> <li>For diarrhea grade 3 or 4 during the prior cycle, reduce doses of all cytotoxic agents by <span style="white-space: nowrap;">25%.<sup>[1]</sup></span> For second occurrence, reduce doses of all cytotoxic agents to 50% of original dose. Discontinue treatment for third occurrence.</li> <li><strong>NOTE:</strong> Severe diarrhea, mucositis, and myelosuppression after FU should prompt evaluation for DPD deficiency. </li> <li>Refer to UpToDate topics on enterotoxicity of chemotherapeutic agents.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Mucositis or palmar-plantar erythrodysesthesia</strong></td> <td colspan="3"> <ul> <li>Do not start a new cycle of therapy unless stomatitis and hand-foot syndrome have resolved to grade 1 or <span style="white-space: nowrap;">less.<sup>[1]</sup></span></li> <li>For grade 3 to 4 toxicity during the prior cycle, reduce doses of all cytotoxic agents by <span style="white-space: nowrap;">25%.<sup>[1]</sup></span> For the second occurrence, reduce doses of all cytotoxic agents to 50% of original dose.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Neurotoxicity</strong></td> <td colspan="3"> <ul> <li>Do not start a new cycle of therapy unless peripheral neurotoxicity is &lt;grade 3 unless benefits outweigh <span style="white-space: nowrap;">risks.<sup>[1]</sup></span></li> <li>For transient grade 3 paresthesias/dysesthesias or grade 2 symptoms lasting more than seven days during the prior cycle, the US Prescribing Information suggests a decrease in the oxaliplatin dose by <span style="white-space: nowrap;">25%.<sup>[3]</sup></span> Discontinue oxaliplatin for grade 4 or persistent grade 3 paresthesia/dysesthesia.</li> <li>There is no recommended dose for resumption of FU administration following development of hyperammonemic encephalopathy, acute cerebellar syndrome, confusion, disorientation, ataxia, or visual disturbances; the drug should be permanently <span style="white-space: nowrap;">discontinued.<sup>[5]</sup></span></li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Dermatologic toxicity</strong></td> <td colspan="3"> <ul> <li>Withhold dose of panitumumab for symptomatic skin- or nail-related toxicity requiring opioids, systemic steroids, or felt to be intolerable by the subject; skin or nail infection requiring IV antibiotic or IV antifungal treatment; need for surgical debridement; or any skin- or nail-related serious adverse <span style="white-space: nowrap;">event.<sup>[1]</sup></span></li> <li>Severe dermatologic reactions, such as acneiform rash, require withholding panitumumab for one dose, then resume at 100% dose if toxicity <span style="white-space: nowrap;">resolves.<sup>[1]</sup></span> For second recurrence, withhold one or two doses, and reduce subsequent dose by 20% once toxicity resolves. For third occurrence, further reduce panitumumab dose by another 20% once toxicity resolves. For fourth occurrence or lack of toxicity resolution for up to three weeks, discontinue panitumumab.</li> <li>Refer to UpToDate topics on acneiform eruption secondary to epidermal growth factor receptor (EGFR) and MEK inhibitors.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Pulmonary toxicity</strong></td> <td colspan="3"> <ul> <li>Oxaliplatin has rarely been associated with pulmonary toxicity. Withhold oxaliplatin for unexplained pulmonary symptoms until interstitial lung disease or pulmonary fibrosis is excluded.</li> <li>Permanently discontinue panitumumab in patients developing pulmonary fibrosis/interstitial lung <span style="white-space: nowrap;">disease.<sup>[6]</sup></span></li> <li>Refer to UpToDate topics on pulmonary toxicity associated with antineoplastic therapy, cytotoxic agents and pulmonary toxicity associated with antineoplastic therapy, molecularly targeted agents.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Cardiotoxicity</strong></td> <td colspan="3"> <ul> <li>Cardiotoxicity observed with FU includes myocardial infarction/ischemia, angina, dysrhythmias, cardiac arrest, cardiac failure, sudden death, ECG changes, and cardiomyopathy. There is no recommended dose for resumption of FU administration following development of cardiac toxicity, and the drug should be <span style="white-space: nowrap;">discontinued.<sup>[5]</sup></span></li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1"><strong>Other toxicity</strong></td> <td colspan="3"> <ul> <li>Any other grade 3 or 4 toxicity except anemia and alopecia can justify dose reduction for all cytotoxic agents by <span style="white-space: nowrap;">25%.<sup>[1]</sup></span></li> </ul> </td> </tr> <tr class="divider_top"> <td class="highlight_gray_text" colspan="4" style="font-size: 1.2em;"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class="graphic_lgnd"><strong>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</strong></div><div class="graphic_footnotes">IV: intravenous; NS: normal saline; D5W: 5% dextrose in water; G-CSF: granulocyte colony stimulating factors; QT: time between the start of the Q wave and the end of the T wave (heart electrical cycle); ECG: electrocardiogram; CBC: complete blood count; DPD: dihydropyrimidine dehydrogenase.<br/>
¶ For patients with potentially resectable liver metastases, the number of preoperative chemotherapy courses should be limited to no more than six or eight (three to four months of therapy) to limit the potential for postoperative hepatic morbidity. The protocol could then be continued as adjuvant treatment for a total of 12 perioperative cycles.<sup>[1]</sup><br/>
Δ Doses higher than 1000 mg should be diluted to 150 mL with NS<sup>◊</sup> and administered over 90 rather than 60 minutes.<br/>
<span class="lozenge">◊</span> Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).<br/>
§ If the first panitumumab dose is well tolerated, subsequent infusions can be given over 30 minutes.<br/>
¥ A lower initial dose of irinotecan should be considered for patients with poor performance status, prior pelvic or abdominal radiotherapy, or increased bilirubin levels.<sup>[4]</sup> Whether a reduced starting dose is needed in patients who are homozygous for the UGT 1A1*28 allele (Gilbert syndrome) and whether testing for this allele should be carried out prior to starting irinotecan is controversial. Refer to UpToDate topic on "Enterotoxicity of chemotherapeutic agents".<br/>
‡ Many centers routinely infuse oxaliplatin via central venous line because of local pain with infusion into a peripheral vein.<br/>
† Leucovorin dose is given for the d,l racemic mixture. Give one-half the dose (200 mg/m<sup>2</sup>) if using LEVOleucovorin (l-leucovorin, Fusilev).<sup>[7]</sup><br/>
** At many institutions, regimens that combine oxaliplatin with irinotecan on day 1 are considered highly emetogenic, warranting the use of a neurokinin-1 receptor antagonist on day 1. The National Comprehensive Cancer Network considers this and similar regimens as moderately emetogenic.</div><div class="graphic_reference">References:
<ol>
<li>Modest DP, et al. J Clin Oncol 2019; 37:3401.</li>
<li>Masi G, et al. Ann Oncol 2004; 15:1766.</li>
<li>Oxaliplatin injection. United States Prescribing Information. US National Library of Medicine. (Available online at <a href="https://dailymed.nlm.nih.gov/dailymed/" target="_blank">dailymed.nlm.nih.gov</a>, accessed on August 30, 2016).</li>
<li>Irinotecan hydrochloride injection. United States Prescribing Information. US National Library of Medicine. (Available online at <a href="https://dailymed.nlm.nih.gov/dailymed/" target="_blank">dailymed.nlm.nih.gov</a>, accessed on August 30, 2016).</li>
<li>Fluorouracil injection. United States Prescribing Information. US National Library of Medicine. (Available online at <a href="https://dailymed.nlm.nih.gov/dailymed/" target="_blank">dailymed.nlm.nih.gov</a>, accessed on August 30, 2016).</li>
<li>Panitumumab injection. United States Prescribing Information. US National Library of Medicine. (Available online at <a href="https://dailymed.nlm.nih.gov/dailymed/" target="_blank">dailymed.nlm.nih.gov</a>, accessed on July 23, 2018).</li>
<li>Levoleucovorin calcium injection. United States Prescribing Information. US National Library of Medicine. (Available online at <a href="https://dailymed.nlm.nih.gov/dailymed/" target="_blank">dailymed.nlm.nih.gov</a>, accessed on August 30, 2016).</li>
</ol></div><div id="graphicVersion">Graphic 126434 Version 5.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
